Ludwig Enterprises, INC

Ludwig Enterprises, Inc. has secured $250,000 in financing through a convertible promissory note and a common stock purchase warrant from Alumni Capital LP.

Ludwig Enterprises, Inc. announced the appointment of Jose Antonio Reyes as its Interim Chief Executive Officer, effective October 1, 2025.

Ludwig Enterprises, Inc. announced the immediate appointment of Corain McGinn, an experienced executive and attorney, as an Independent Director to its Board.

Ludwig Enterprises, Inc. announced the resignation of its Chief Executive Officer, Charles T. Todd Jr., effective August 23, 2025, with a 30-day transition period.

Ludwig Enterprises, Inc. announced the appointment of Garth Lees-Rolfe, a seasoned finance and accounting professional with extensive biotech industry experience, as a new independent director to its Board.

Ludwig Enterprises, Inc. announced that Dr. Marvin S. Hausman has resigned from its Board of Directors, though he will continue in his role as Chief Scientific Officer, with no disagreements cited.

Ludwig Enterprises reported a net income of $218,847 for Q1 2026, driven primarily by non-cash gains rather than operational revenue.

Ludwig Enterprises reported a net income of $31,252 for Q3 2025, a significant improvement from previous losses, but faces substantial doubt about its ability to continue as a going concern due to significant deficits and cash burn.

Ludwig Enterprises, a healthcare technology developer, reported significant financial deficits and a going concern warning, despite a reduced net loss.

Ludwig Enterprises, Inc. reports a decreased net loss for Q1 2025 compared to Q1 2024, as it prepares to launch new products and manages its debt obligations.

Ludwig Enterprises reported a net loss of $2.86 million for the nine months ended September 30, 2024, and faces substantial doubt about its ability to continue as a going concern.

Ludwig Enterprises reported a net loss of $1.975 million for the six months ended June 30, 2024, as the company continues to develop its healthcare technology products.

Ludwig Enterprises, an early-stage genomic diagnostics company, reported significant losses and a going concern warning in its 2025 annual report, despite advancing its Revealia Breast test towards a Q2 2026 trial launch.

Ludwig Enterprises, Inc. reports its annual results for 2024, highlighting its focus on developing mRNA-based genomic technology for early detection of inflammatory diseases.

Ludwig Enterprises Inc. released its 2023 annual report, detailing its focus on mRNA technology for disease detection and treatment, while also acknowledging significant financial losses and a going concern warning.

Reporting person Marvin S. Hausman MD disclosed the sale of 2,000,000 shares of Ludwig Enterprises, Inc. common stock.

Shareholders have approved a reverse stock split, a corporate name change to Revealia Diagnostics, Inc., and significant amendments to corporate governance documents to facilitate a potential Nasdaq listing.

Ludwig Enterprises, Inc. will change its corporate name to Revealia, Inc. after securing shareholder approval via written consent.

Ludwig Enterprises, an early-stage genomics company, is seeking to raise approximately $13.55 million through a firm commitment public offering of common units to fund clinical studies and commercialize its mRNA-based breast cancer test.

Ludwig Enterprises, an early-stage genomics company, filed an S-1/A for a public offering to fund its operations and advance its non-invasive breast cancer diagnostic test, despite significant losses and going concern doubts.

Ludwig Enterprises, Inc., a genomics technology company, has filed an S-1 registration statement for a firm commitment public offering to fund the development and launch of its mRNA genetic testing kits.